Personalized medicine is gaining momentum and changing the landscape of healthcare globally. MiRNA is a novel class of genetic material discovered only at the dawn of the 21st century but has continuously made headlines in biomedical research worldwide. Distinct from DNA mutations, miRNA expression level changes during disease state and offers valuable information in detecting disease onset and monitoring disease progression and recurrence. Unlike other genetic materials, miRNA is exceptional stable and accessible in biofluids, making it an ideal candidate biomarker for non-invasive blood based test. MiRNA research has been growing exponentially worldwide with Frost and Sullivan bullishly projected that “advance in microRNA is predicting future in vitro diagnostic market”.
(Evidence: 3 case-control cohorts, multi-ethnicity, N>900)
(Evidence: 3 case-control cohorts, multi-ethnicity, N>800)
(Evidence: 3 case-control cohorts, multi-ethnicity, N>1200)